Cullinan Oncology LLC (CGEM) - Stock & Dividends

Cullinan Oncology LLC (NASDAQ:CGEM) is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. They are dedicated to developing targeted oncology and immuno-oncology therapies for cancer patients in the United States.

The company's primary focus is on advancing innovative treatments for cancer, with their lead candidate being the CLN-081. This orally bioavailable small-molecule is currently undergoing a Phase IIb dose escalation study for non-small cell lung cancer.

Alongside CLN-081, Cullinan Oncology LLC is working on a range of other promising products. These include CLN-049, a humanized bispecific antibody for acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody for solid tumors; and CLN-418, a bispecific antibody for solid tumors, all of which are in various stages of clinical trials.

In addition to their clinical pipeline, the company is also actively developing preclinical products like CLN-617, a fusion protein for solid tumors, and CLN-978, a T cell engaging antibody for B-cell non-Hodgkin lymphoma that has relapsed or is refractory to treatment.

Collaboration agreements with Cullinan Pearl Corp. and Adimab, LLC further enhance Cullinan Oncology LLC's capabilities. These partnerships focus on developing and optimizing their treatments to benefit cancer patients.

Established in 2016, Cullinan Oncology LLC is driven by a mission to make significant advancements in cancer therapy, ultimately aiming to improve outcomes and quality of life for those affected by the disease. To learn more about their work, visit their website at https://www.cullinanoncology.com.